Eluminex is committed towards developing first- and/or best-in-class innovative pharmaceuticals, drug delivery systems, and regenerative tissue for significant unmet vision-threatening or lifestyle limiting ophthalmic diseases in China and global markets.
Eluminex Biosciences is a privately held ophthalmology-focused biotechnology company founded in early 2020. The leadership team comprises over 100 years of cumulative global drug development experience in ophthalmology with a longstanding track record of success. Our expertise allows for evaluation of therapeutic opportunities for both anterior and posterior segment diseases. Our company headquarters and research and development (R&D) facility is located in Suzhou BioBAY, China and our US regional office is located in the biotech corridor of South San Francisco, California in the San Francisco Bay Area.
Our state-of-the-art R&D facility in the Suzhou BioBAY is under construction with completion expected in the third quarter of 2021. The nearly 24,000 square feet (2,200 sqm) R&D center will allow the full range of basic science research and drug discovery, formulation development, and validating preclinical/chemistry, manufacturing and control (CMC) studies in support of investigational new drug applications (IND) for small molecules, proteins, drug delivery, and regenerative medicine.
Eluminex Biosciences location at Suzhou BioBay headquarters and interior design.
Completion of headquarter facilities expected in August 2021.
Eluminex Biosciences San Francisco Bay Area Office.
Message from the CEO
I am pleased to welcome you to the inaugural website of Eluminex Biosciences. The company was founded in early 2020 aiming at harnessing innovative science to develop the next generation of therapeutic products in ophthalmology for China and global markets.
I am pleased to welcome you to the inaugural website of Eluminex Biosciences. The company was founded in early 2020 aiming at harnessing innovative science to develop the next generation of therapeutic products in ophthalmology for China and global markets. Our first significant milestone was the completion of $50 million (USD) Series A funding in November 2020 with the support of three premier venture capitals, Lilly Asia Ventures, GL Ventures of the Hillhouse Capital, and Quan Capital that has allowed us to develop our initial pipeline of novel protein therapeutics and in-license clinical stage assets. A subsidiary in South San Francisco, California was established in January 2021 to support our global clinical development and registration process. The construction of our research and development headquarters in Suzhou BioBay, China will be completed in August 2021. We have assembled a seasoned management team with proven track record of success in ophthalmic drug research and development, including the development of ranibizumab (LUCENTIS®) and lifitegrast (XIIDRA®). Our goal is to strive to make a difference for patients around the world with vision-threatening and/or lifestyle limiting ophthalmic diseases.
Jinzhong (JZ) Zhang, PhD
CO-FOUNDER, CHAIRMAN, AND CEO